LONDON (Alliance News) - Scancell Holdings PLC said Monday that it has seen positive data from its on-going phase I/2 clinical trial of SCIB1 ImmunoBody which it will present at JP Morgan's 33rd Annual Healthcare Conference in San Francisco over the next three days.
The company said that the overall median survival or part 1 patients with tumour present at trial entry who received at least three doses of 2-8 milligrams of SCIB1 is two years. This compares positive with first line untraded Stage UV disease, where patients with no visceral disease had a media survival of 11 months, and patients with visceral disease had a median survival of six months, Scancell said.
Additionally, the status of patients with resected tumours at study entry is "equally promising", the company said.
Part 2 patients have a median survival time of 28 months since study entry, the company said, and all resected patients are still alive with median survival time of 30 months and 27 months for stage III and IV patients respectively, it said.
"The maturing clinical data from our lead ImmunoBody®, SCIB1, continues to enhance our confidence in the clinical value of SCIB1 as monotherapy, especially in the adjuvant setting, a huge and relatively untapped market," said Joint Chief Executive Richard Goodfellow in a statement.
Shares in Scancell are trading up 3.9% at 32.74 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)